Starling Oncology, Inc. STLN PHARMA
Company Overview
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Why Investors Should Care
Revenue has grown at a 21.8% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $502.73M (+27.8% YoY); net profit $-60.61M.
- Trailing 12 Months Year-on-year growth — revenue +34.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 21.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 21.80% |
| 1 Year: | 34.60% |
Stock Price Performance
| 1 Year: | +54.15% |
| 6 Months: | +131.50% |
| 3 Months: | +24.65% |
| 1 Month: | -1.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.13 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 21.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | STLN Starling Oncology, Inc. PHARMA | 6.32 | -21.79 | $644.11M | 0.00% | -38.51% | - | 21.80% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 48.58M | 49.84M | 52.27M | 55.16M | 60.92M | 64.98M | 76.19M | 80.22M | 82.03M | 94.67M | 98.58M | 99.90M | 104.41M | 119.80M | 136.56M | 147.44M | 161.28M |
| Operating Income | -2.30K | -87.77K | -194.56K | -198.48K | -1.75M | -1.12M | -2.16M | -18.47M | -18.30M | -20.10M | -32.87M | -14.94M | -13.93M | -17.97M | -16.36M | -13.85M | -9.91M | -11.21M | -8.05M | -6.51M | -4.62M |
| Net Income | -2.30K | -776.84K | -2.62M | -2.42M | -996.00K | 3.21M | -2.98M | 19.29M | -5.45M | -2.67M | -30.00M | -16.90M | -17.42M | -19.89M | -15.48M | -16.11M | -19.59M | -17.01M | -16.50M | -2.49M | -9.79M |
| Diluted EPS | - | - | - | - | -0.02 | 0.05 | -0.05 | 0.21 | -0.06 | -0.17 | -0.33 | -0.19 | -0.19 | -0.22 | -0.17 | -0.18 | -0.21 | -0.15 | -0.14 | -0.02 | -0.08 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 187.51M | 203.00M | 252.48M | 324.24M | 393.41M | 502.73M |
| Operating Income | -8.20M | -45.86M | -81.95M | -77.02M | -60.12M | -36.08M |
| Net Income | -14.32M | -10.93M | 152.00K | -83.07M | -64.66M | -60.61M |
| Diluted EPS | -0.24 | -0.16 | -0.21 | -0.92 | -0.71 | -0.54 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 50.00K | 65.69M | 203.44M | 261.67M | 209.24M | 172.72M | 164.66M |
| Total Equity | 0 | 42.22M | 28.10M | 104.16M | 123.17M | 57.02M | 3.59M | -15.72M |
| Cash & Equivalents | - | - | 900.00K | - | - | - | - | - |
| Long Term Debt | - | - | 6.56M | 0 | 80.62M | 86.83M | 93.13M | 77.40M |
| Total Liabilities | - | 27.30K | 37.59M | 99.28M | 138.49M | 152.22M | 169.13M | 180.38M |
| Current Liabilities | - | 27.30K | 28.61M | 29.80M | 29.72M | 34.79M | 52.22M | 70.96M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 508.00K | -32.68M | -61.76M | -36.31M | -26.54M | -24.59M |
| Investing Cash Flow | -8.84M | -12.15M | -131.61M | 62.64M | 46.21M | -3.07M |
| Financing Cash Flow | 11.89M | 154.01M | 92.21M | -6.85M | -3.49M | 11.56M |
| Capital Expenditure | -1.19M | -2.85M | -5.53M | -4.57M | -3.79M | -3.20M |
| Free Cash Flow | -686.00K | -35.53M | -67.28M | -40.88M | -30.33M | -27.79M |
| Share Buybacks | - | 0 | 9.00M | 1.02M | 0 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -4.4% | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% |
| Net Margin % | -7.6% | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
| ROE % | -51.0% | -10.5% | 0.1% | -145.7% | -1,801.7% | 385.5% |
| ROCE % | -22.1% | -26.4% | -35.3% | -44.1% | -49.9% | -38.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 4.75% | 4.75M | $33.05M |
| 2 | Deerfield Management Company, L.P | 3.36% | 3.36M | $23.39M |
| 3 | Vanguard Capital Management LLC | 3.27% | 3.27M | $22.73M |
| 4 | Josh Arnold Investment Consultant, Llc | 2.46% | 2.46M | $17.15M |
| 5 | Geode Capital Management, LLC | 1.90% | 1.90M | $13.22M |
| 6 | Goldman Sachs Group Inc | 1.74% | 1.74M | $12.08M |
| 7 | Wexford Capital LP | 1.71% | 1.71M | $11.91M |
| 8 | State Street Corporation | 1.55% | 1.55M | $10.81M |
| 9 | Nuveen, LLC | 1.41% | 1.41M | $9.80M |
| 10 | Renaissance Technologies, LLC | 1.37% | 1.37M | $9.51M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for STLN
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9tVkpSY2w1aDFsbUxjWEh6YTlKM0tscG80dVQxVTc1NTJHU3IyVlhhU0FudktuWmxKTDVTcE9QTG1mVURHVHRUTUhTcVE1amtq?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
(STLN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOZzdVVWhDY2UyUFloZGRXSVl0bmY5b3JGTi1XY1FsTm5Yc2cyb0Y1OEJrYlN5MkdrNWNTZ2tDa2NtMDhXRWdPNk8xNTloTm5HUFFPZGp0M1U2VHRKdGdubWVDUWdnREM4cXdkWEkxbkJ1UW5MVmpkQ28wd2pLWDRXX3RiTFJnSlZNVXNyVz…
Oncology Institute (NASDAQ:STLN) Stock Price Down 4.4% - What's Next? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNeFozS3lBamdwRHdJUGhPU0FtVW9XaFN2bUIwNk83aGFYZ2VlSElpWWZXbFVTMU8wUXNlMnMxU01DYnFsMk5IS0NvOVYwbmxXZVVwcjRMakF1NDNMUkZTc3MyUVU1S0pGQUZCZ1lpVGZaNXh3T2hqeFE5ZU9nVHgzeHZGbk84aFhVZXRxdG…
Earnings To Watch: Starling Oncology Inc (STLN) Q2 2026 -- GF Value Sees 44% Downside - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOTElTeEtjVEtPc29sSVY1WjVvcERoOUFaV1luR1N5TTZqRHFGZVlIRzRyOGI4VjBSVkdjU0M1VmxQMlFadDNGaDNPaVJncnNIbDg1bi15c0ZnOFJpSFAtbVhhWGJUSm1ULXFvQ2l5UzZnWnBCWE5TdHFMX0gxWDB6RlRlYVpGNFVNSE1mVl…
Starling Oncology (STLN) Stock Price, News & Analysis - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE5GSDJQTWZyaEdSS3JjZHZvUVBHdEhhRlcwbW9qSmJKOG1VVGhyU1pLdU9qQTRIRGpwa3hkS01EdmtweElBXzgyaUREczRwOWxBMlNF?oc=5" target="_blank">Starling Oncology (STLN) Stock Price, News & Analysis</…
US$9.00 - That's What Analysts Think Starling Oncology, Inc. (NASDAQ:STLN) Is Worth After These Results - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxOZ3ZnWE1xTjhHSmlfZklVYnhZV3JfVlpUcDUyOF9jSmdHUXJwUXRpaFN1SUNOZnZ0VjdKbm5SVXlsdVYzTksyNEJtU2YxSjlwUFRWeExfdFBlOF83QzhnN2RYNy1WR2U2QnBpN3NORUZtUzFnSW14bmt4Y0t5NlRFSURrNXpDcnFtd0JRQT…
STLN — Frequently Asked Questions
What is the current share price of Starling Oncology, Inc. (STLN)?
As of 2026-09-19 21:16 PDT, Starling Oncology, Inc. (STLN) trades at $6.32 on NasdaqCM. Its 52-week range is $2.38 to $6.66.
What is the market capitalisation of STLN?
Starling Oncology, Inc. (STLN) has a market capitalisation of $644.11M on NasdaqCM.
What is the P/E ratio of STLN?
STLN trades at a trailing price-to-earnings (P/E) ratio of -21.79. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -28.06.
Is STLN a good stock to buy?
This page provides a data-driven analysis of Starling Oncology, Inc. (STLN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.